Covid-19 roundup: Vaxart dos­es first pa­tient in new clin­i­cal vac­cine study; NI­AID launch­es study to find po­ten­tial ther­a­pies in re­pur­posed drugs

Cal­i­for­nia-based Vaxart has dosed the first pa­tient in a Phase I study of its Covid-19 can­di­date.

The oral can­di­date, VXA-CoV2-1, will be test­ed in up to 48 vol­un­teers ages 18 to 54 years old. The biotech ex­pects to com­plete en­roll­ment by ear­ly No­vem­ber, and re­ceive the first clin­i­cal da­ta in the next few weeks. The vac­cine could be a one- or two-dose can­di­date, de­pend­ing on the out­come of the study.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN